4.7 Article

SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia

期刊

BLOOD
卷 121, 期 1, 页码 148-155

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-05-428938

关键词

-

资金

  1. ECOG leukemia tissue bank
  2. National Institutes of Health(NIH)/National Cancer Institute (NCI) [R01CA137060, R01CA139032, R01CA157644, R01CA169458, R21CA152497]
  3. NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [R01AR54153]
  4. Leukemia & Lymphoma Society [6132-09, 6097-10, 6221-12, 7005-11]
  5. William Lawrence and Blanche Hughes Foundation and a Stand Up To Cancer-American Association for Cancer Research Innovative Research Grant [IRG00909]
  6. California Institute for Regenerative Medicine (CIRM) [TR2-01 816]

向作者/读者索取更多资源

The Sox4 transcription factor mediates early B-cell differentiation. Compared with normal pre-B cells, SOX4 promoter regions in Ph+ ALL cells are significantly hypomethylated. Loss and gain-of-function experiments identified Sox4 as a critical activator of PI3K/AKT and MAPK signaling in ALL cells. ChIP experiments confirmed that SOX4 binds to and transcriptionally activates promoters of multiple components within the PI3K/AKT and MAPK signaling pathways. Cre-mediated deletion of Sox4 had little effect on normal pre-B cells but compromised proliferation and viability of leukemia cells, which was rescued by BCL2L1 and constitutively active AKT and p110 PI3K. Consistent with these findings, high levels of SOX4 expression in ALL cells at the time of diagnosis predicted poor outcome in a pediatric clinical trial (COG P9906). Collectively, these studies identify SOX4 as a central mediator of oncogenic PI3K/AKT and MAPK signaling in ALL. (Blood. 2013; 121(1): 148-155)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据